Clinical trialNCT06797518RecruitingPhase 2Interventional

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

SponsorNovartis PharmaceuticalsEnrollment20Glomerulonephritis, IGAImmunoglobulin A Nephropathy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease progression, including but not limited to Oxford MEST-C score.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Recruiting

Israel

Novartis Investigative Site
Ashdod, Israel
Recruiting
Novartis Investigative Site
Hadera, Israel
Recruiting
Novartis Investigative Site
Haifa, Israel
Recruiting
Novartis Investigative Site
Nahariya, Israel
Recruiting

Malaysia

Novartis Investigative Site
Kuala Lumpur, Kuala Lumpur, Malaysia
Recruiting
Novartis Investigative Site
Kuala Lumpur, Selangor, Malaysia
Recruiting

Saudi Arabia

Novartis Investigative Site
Riyadh, Saudi Arabia
Recruiting

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Dana Rizk
Recruiting
Ucla Medical Center
Los Angeles, California, United States
Mrinalini Sarkar
Recruiting
Central Florida Kidney Specialists
Orlando, Florida, United States
Arvind Madan
Recruiting
Georgia Nephrology Research Inst
Lawrenceville, Georgia, United States
James A Tumlin
Recruiting
Care Research
Chubbuck, Idaho, United States
Hira Siktel
Recruiting
Davita Clinical Research
Las Vegas, Nevada, United States
Mark Vishnepolsky
Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Andrew Lazar
Recruiting
Osu Wexner Medical Center
Columbus, Ohio, United States
Isabelle Ayoub
Recruiting
Prolato Clinical Research Center
Houston, Texas, United States
Sreedhar Mandayam
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Iptacopan →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Feb 2025
Primary completion: 27 Nov 2027
Completion: 27 Nov 2027
Last update posted: 29 Jul 2026
Registered enrollment: 20
Registry id: NCT06797518

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.